Candel Therapeutics, Inc. (NASDAQ:CADL) Insider Charles Schoch Sells 5,000 Shares

Candel Therapeutics, Inc. (NASDAQ:CADL) insider Charles Schoch sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $8.83, for a total transaction of $44,150.00. Following the completion of the transaction, the insider now owns 38,038 shares in the company, valued at approximately $335,875.54. This represents a 11.62 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Candel Therapeutics Stock Up 0.9 %

CADL traded up $0.08 during mid-day trading on Wednesday, reaching $8.90. 640,009 shares of the company traded hands, compared to its average volume of 2,651,855. The company’s fifty day moving average price is $8.23 and its 200-day moving average price is $6.98. The stock has a market capitalization of $289.04 million, a P/E ratio of -5.14 and a beta of -1.29. Candel Therapeutics, Inc. has a 52-week low of $1.40 and a 52-week high of $14.60.

Candel Therapeutics (NASDAQ:CADL) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.17). As a group, sell-side analysts forecast that Candel Therapeutics, Inc. will post -1.47 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on CADL. HC Wainwright restated a “buy” rating and issued a $19.00 price objective on shares of Candel Therapeutics in a report on Friday, March 14th. Bank of America assumed coverage on Candel Therapeutics in a research note on Friday, February 7th. They issued a “buy” rating and a $15.00 price target for the company. Canaccord Genuity Group increased their price objective on Candel Therapeutics from $20.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, February 26th. Finally, Citigroup started coverage on Candel Therapeutics in a research report on Thursday, February 20th. They issued a “buy” rating and a $25.00 target price for the company.

Hedge Funds Weigh In On Candel Therapeutics

Several institutional investors have recently made changes to their positions in the business. MetLife Investment Management LLC increased its holdings in Candel Therapeutics by 9.7% during the fourth quarter. MetLife Investment Management LLC now owns 13,773 shares of the company’s stock valued at $120,000 after buying an additional 1,215 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Candel Therapeutics by 12.4% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,165 shares of the company’s stock worth $106,000 after acquiring an additional 1,340 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Candel Therapeutics by 15.2% during the 4th quarter. JPMorgan Chase & Co. now owns 10,426 shares of the company’s stock valued at $90,000 after acquiring an additional 1,375 shares during the period. Russell Investments Group Ltd. increased its stake in shares of Candel Therapeutics by 75.1% in the 4th quarter. Russell Investments Group Ltd. now owns 3,753 shares of the company’s stock worth $33,000 after purchasing an additional 1,610 shares in the last quarter. Finally, Nuveen Asset Management LLC raised its holdings in Candel Therapeutics by 3.0% in the 4th quarter. Nuveen Asset Management LLC now owns 68,226 shares of the company’s stock worth $592,000 after purchasing an additional 2,009 shares during the period. Institutional investors own 13.93% of the company’s stock.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.